Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 17/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9952185 | 0.86 | MAOB (0.47) | SLC6A4BRD4CREBBPHCRTR1HCRTR2 | |
| SCHEMBL9951225 | 0.86 | BRD4 (0.44) | BRD4CREBBP | |
| SCHEMBL9952168 | 0.86 | BRD4 (0.46) | SLC6A4BRD4CREBBP | |
| SCHEMBL4138667 | 0.83 | BRD4 (0.56) | SLC6A4BRD4CREBBP | |
| SCHEMBL9950246 | 0.82 | NPC1 (0.45) | SLC6A4BRD4CREBBPCYP3A4 | |
| SCHEMBL9951126 | 0.81 | HTR6 (0.43) | SLC6A4BRD4CREBBP | |
| SCHEMBL9951335 | 0.78 | NPC1 (0.46) | BRD4CREBBPCYP3A4 | |
| SCHEMBL9952174 | 0.77 | ABCB1 (0.48) | SLC6A4BRD4CREBBP | |
| SCHEMBL10029547 | 0.77 | HTR6 (0.53) | SLC6A4BRD4CREBBP | |
| SCHEMBL27880925 | 0.76 | HCRTR1 (0.41) | SLC6A4HCRTR1HCRTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | claimed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-9493419-B2 | Quinoline derivatives as anti-cancer agents | THE HONG KONG POLYTECHNIC UNIVERSITY (HK) | 2016-11-15 | — | — | US | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
| WO-2012083866-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012083866-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | WO | disclosed |
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165370-A1 | QUINOLINE DERIVATIVES AS ANTI-CANCER AGENTS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HKDC1, HK1 | SLC6A4 2502/4885BRD4 111/4885CREBBP 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.